Tacalyx Secures €11M to Advance 'Undruggable' Cancer-Targeting ADC

BERLIN, Germany – April 29, 2026 – German biotech firm Tacalyx announced today it has secured €11 million in a seed extension round to advance its pioneering work in oncology. The funding will propel its first clinical candidate, TCX-201, through preclinical development, with the goal of filing for clinical trials in 2027. The move signals a critical transition for the company, moving from discovery research into clinical development and closer to tackling a class of cancer targets long considered “undruggable.”

The financing was provided by the company’s existing international investor syndicate, a group of top-tier European life sciences funds including Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, High-Tech Gründerfonds (HTGF), Eurazeo, Creathor Ventures, and Thuja Capital. This strong vote of confidence from current backers underscores the significant progress Tacalyx has made in its mission to develop therapies against Tumour Associated Carbohydrate Antigens (TACAs).

TCX-201 is an antibody-drug conjugate (ADC) developed to treat gastrointestinal malignancies and other solid tumours, a field with substantial unmet medical need. The financing will support the necessary preclinical activities for TCX-201 while also enabling Tacalyx to expand its broader pipeline of novel cancer treatments.

Cracking the Code of Cancer's Sugary Coat

At the heart of Tacalyx's strategy is a focus on TACAs—unique sugar structures that coat the surface of cancer cells. These aberrant glycans are either overexpressed on tumour cells or absent entirely from healthy tissue, making them highly specific markers for cancer. They play a critical role in tumour progression, aiding in cell adhesion, immune system evasion, and metastasis. This unique expression profile makes them ideal targets for developing highly selective therapies that can attack cancer cells while sparing healthy ones.

Despite this promise, TACAs have historically been a frustrating frontier in oncology. Their complex and heterogeneous structures, combined with a low immunogenicity that makes them difficult for the immune system to recognize, have made them notoriously difficult to target with conventional antibody approaches. This has left a vast and promising therapeutic landscape largely unexplored.

Tacalyx, a 2019 spin-out from the world-renowned Max-Planck-Institute of Colloids and Interfaces, was founded specifically to overcome these challenges. Leveraging the foundational work of its scientific co-founders, Prof. Dr. Peter Seeberger and Dr. Oren Moscovitz, the company has built a proprietary technology platform capable of reliably generating high-affinity and highly specific antibodies against these complex carbohydrate targets. This breakthrough technology effectively makes the previously “undruggable” druggable, opening the door to a new class of cancer therapies.

“Tacalyx has delivered on its promise to unlock the therapeutic potential of TACAs, a frontier in oncology that has long been considered undruggable,” said Klaus Schollmeier, Chairman of the Board of Tacalyx. “With the selection of its first clinical candidate and significant advances with its earlier pipeline, the company is now rapidly transitioning from discovery research to a clinical-stage biotech.”

A Strategic Transition Fueled by Investor Confidence

The €11 million seed extension represents more than just financial fuel; it is a powerful endorsement of Tacalyx's platform and strategy. The continued participation of its entire existing investor syndicate, which includes the venture arm of a major pharmaceutical company and several of Europe's most respected life science funds, highlights a deep-seated belief in the company's potential to create a new paradigm in cancer treatment.

These investors, known for backing high-risk, high-reward innovations, see the value in Tacalyx’s approach to solving a long-standing scientific problem. The funding will enable the company to complete the rigorous and costly preclinical studies required for TCX-201, including toxicology and manufacturing scale-up, to prepare for its first-in-human trials.

“Over the past years, we have built a powerful platform capable of reliably discovering and developing high-affinity antibodies against TACAs, sugar structures specifically found on tumour cells,” stated Jean Engela, CEO of Tacalyx. “Heralding a new stage for the company, Tacalyx has selected a clinical candidate for its TCX-201 programme and is now progressing preclinical activities to prepare for the CTA submission. With that, we are now redoubling our laser focus on translating the cutting-edge science on which the company was founded into transformative cancer therapies. Cancer patients cannot wait.”

TCX-201: A 'Smart Bomb' for Hard-to-Treat Cancers

TCX-201 is an antibody-drug conjugate (ADC), a class of therapeutics often described as “biological missiles” or “smart bombs.” ADCs work by linking a highly potent cytotoxic agent (the payload) to a monoclonal antibody that targets a specific antigen on cancer cells. In this case, the antibody is one of Tacalyx’s highly specific TACA-targeting antibodies. This design allows for the direct delivery of a powerful cancer-killing drug to the tumour site, minimizing systemic exposure and the collateral damage to healthy tissues that is common with traditional chemotherapy.

The initial focus for TCX-201 on gastrointestinal malignancies addresses a significant global health crisis. GI cancers, including stomach, colorectal, and pancreatic cancers, account for one in four cancer cases and one in three cancer-related deaths worldwide. For patients with advanced or metastatic disease, treatment options are often limited and outcomes remain poor, creating a desperate need for novel therapeutic strategies.

The market for ADC therapies is one of the hottest areas in oncology, projected to grow into a multi-tens-of-billions-dollar market within the next decade. While crowded with drugs targeting well-known antigens like HER2 and Trop-2, Tacalyx’s approach provides a differentiated strategy. By pursuing a novel class of targets, TCX-201 could provide a new line of attack for tumours that lack actionable genomic alterations or have developed resistance to existing therapies. As Tacalyx advances its lead program and plans for the selection of its next clinical candidate by the end of 2026, it is positioning itself not just as a participant in the ADC boom, but as an innovator poised to expand the very definition of what is targetable in oncology.